Clinical Trials Directory

Trials / Completed

CompletedNCT02229006

Sodium Fluoride Imaging of Abdominal Aortic Aneurysms

SoFIA3: Sodium Fluoride Imaging (18F-NaF PET-CT) in Abdominal Aortic Aneurysms

Status
Completed
Phase
Study type
Observational
Enrollment
96 (actual)
Sponsor
University of Edinburgh · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether Sodium Fluoride imaging (using Positron Emission Tomography-Computed Tomography - PET-CT) is able to help predict the rate of abdominal aortic aneurysm expansion.

Detailed description

Ruptured abdominal aortic aneurysms (AAAs) have a 90% mortality rate but there are currently no accurate methods of establishing the risk of rupture for an individual patient with an asymptomatic AAA. In vascular disease, microcalcification occurs in response to necrotic inflammation. Using computed tomography and positron emission tomography (PET-CT), early micro calcification can be identified using uptake of the radiotracer 18F-sodium fluoride. This can identify high risk-lesions in the aorta, coronary and carotid arteries, and appears to be indicative of necrotic and heavily inflamed tissue. The study investigators therefore propose to evaluate the ability of 18F-sodium fluoride to identify regions of necrotic inflammation in AAA and predict AAA expansion. The study investigators will explore its value as part of an ongoing clinical trial assessing the identification of macrophage activity using magnetic resonance imaging - the MA3RS Study (ISRCTN76413758). Patients already enrolled in the MA3RS Study will be recruited for the SoFIA3 study. Control patients with a normal calibre aorta will be recruited from the National AAA Screening Programme.

Conditions

Interventions

TypeNameDescription
RADIATION18F-NaF PET-CT

Timeline

Start date
2014-09-01
Primary completion
2017-01-01
Completion
2017-02-01
First posted
2014-08-29
Last updated
2017-05-17

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02229006. Inclusion in this directory is not an endorsement.